Acalisib

产品编号: DC8760 Featured
Acalisib
结构式
870281-34-8
此产品仅供科研所需,我们不出售给病人
​我们将匹配市场上最好的价格给您
Email:order@dcbio.cn
免费咨询电话:4008862077
我们的合作伙伴:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
中国地区超过5000个高品质化合物库存
应用领域
Acalisib 是一种有效的选择性 PI3Kδ 抑制剂,IC50 为 12.7 nM。
Cas No.: 870281-34-8
名称:
别名: UNII-OVW60IDW1D;Acalisib (GS-9820);
SMILES: C[C@@H](C1N(C2=CC=CC=C2)C(=O)C2=C(C=CC(=C2)F)N=1)NC1=C2C(N=CN2)=NC=N1
分子式: C21H16FN7O
分子量: 401.4
纯度:
保存条件: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description:
In Vivo:
In Vitro:
References: Acalisib (GS-9820) inhibits the activity of PI3K, thereby preventing the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which decreases tumor cell proliferation and induces cell death. Wortmannin, LY294002, GDC0941, IC87114 and Acalisib induced a dramatic retraction of osteoclasts within 15-20 min to 65-75% of the initial area. In contrast, there was no significant retraction in response to vehicle, PIK75, TGX221 or AS252424. Moreover, wortmannin and Acalisib (GS-9820), but not PIK75 or TGX221, disrupted actin belts. Whereas PIK75, TGX221, and Acalisib had no significant effect on basal survival, all blocked RANKL-stimulated survival. PI3K-mediated signaling is often dysregulated in cancer cells; the targeted inhibition of PI3K is designed to preserve PI3K signaling in normal, non-neoplastic cells.
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
产品编号 产品名称 应用领域
DC8760 Acalisib Acalisib 是一种有效的选择性 PI3Kδ 抑制剂,IC50 为 12.7 nM。
DC7238 Gedatolisib(PKI-587) Gedatolisib (PKI-587) 是一种高效的双重 PI3Kα,PI3Kγ 和 mTOR 抑制剂, IC50 分别为0.4 nM,5.4 nM 和 1.6 nM。PKI-587 在 mTOR 复合物 mTORC1 和 mTORC2 中同样有效。
DC5154 BKM120 (NVP-BKM120, Buparlisib) Buparlisib (NVP-BKM120) 是一种 pan-class I PI3K 抑制剂,作用于 p110α/p110β/p110δ/p110γ,IC50 分别为 52 nM/166 nM/116 nM/262 nM。
DC5072 Duvelisib (IPI-145, INK1197) Duvelisib 是一种选择性 p100δ 抑制剂,作用于 p110δ, p110γ, p110β 和 p110α,IC50 分别为 2.5 nM,27.4 nM,85 nM 和 1602 nM。
DC5068 Idelalisib (CAL-101,GS-1101) Idelalisib (CAL-101; GS-1101) 是一种口服有效的高选择性 p110δ 抑制剂,IC50 为 2.5 nM,比 p110δ 和其他 PI3K class I 酶的选择性高 40 到 300 倍。